18010-40-7
18010-40-7
Chemical Structure
Bupivacaine hydrochloride
- CAS No.: 18010-40-7
- Formula:C18H29ClN2O
- Molecular Weight:324.89
IUPAC Name: 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride
InChIKey: SIEYLFHKZGLBNX-UHFFFAOYSA-N
SMILES: O=C(C1N(CCCC)CCCC1)NC2=C(C)C=CC=C2C.Cl
Biological Activity: Bupivacaine hydrochloride is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bupivacaine hydrochloride | 99.85% | Bupivacaine hydrochloride is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bupivacaine hydrochloride (Standard) | 99.99% | Bupivacaine (hydrochloride) (Standard) is the analytical standard of Bupivacaine (hydrochloride). This product is intended for research and analytical applications. Bupivacaine hydrochloride is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bupivacaine-d9 hydrochloride | Bupivacaine-d9 hydrochloride is the deuterium labeled Bupivacaine hydrochloride (HY-B0405A). Bupivacaine hydrochloride is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Casati A, et, al. Bupivacaine, levobupivacaine and ropivacaine: are they clinically different? Best Pract Res Clin Anaesthesiol. 2005 Jun;19(2):247-68. [Content Brief]
- [2]. Dan J, et, al. Inhibition of gastric cancer by local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade. Biomed Pharmacother. 2018 Jul;103:823-828. [Content Brief]
